• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition, Swallowing and Saliva
      • Activities of Daily Living and Occupational Therapy
      • Muscles, Mobility and Exercise
      • Respiratory Care
      • Speech and Communication
      • Voice Preservation
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

Ulefnersen

Background

Ulefnersen (also known as ION363 and previously known as Jacifusen) is an antisense oligonucleotide (ASO) compound owned by Ionis Pharmaceuticals, currently undergoing phase 1-3 clinical trial to assess safety and efficacy in FUS-ALS (Clinicaltrials.gov ID: NCT04768972). The drug previously called Jacifusen, was named after Jaci Hermstad, the first person to receive this treatment, administered under the FDA compassionate use program.

Ulefnersen is an ASO designed to target the Fused in Sarcoma (FUS) gene, which is found to be mutated in 0.3-0.9% of ALS/MND cases, often manifesting early onset and aggressive symptoms (Moens et al., 2025). Mutant FUS is thought to cause the disease through a toxic gain of function mechanism, meaning that the presence of the mutated gene and/or deriving protein harms the cells, causing the disease. Ulefnersen targets the FUS RNA transcript and prevents its translation to protein, determining a lower expression of the FUS protein (Korobeynikov et al., 2022).

Preclinical data from a FUS-ALS mouse model showed that treatment with ulefnersen led to reduced FUS protein levels and delayed motor neuron loss. Under a compassionate use/expanded access program, ulefnersen was administered to a 25-year-old woman with juvenile FUS-ALS (JH) 6 months after clinical onset. Upon treatment, her rate of functional decline score (ALSFRSR) slowed. Tragically, JH died nearly a year after initial treatment for worsening of ventilatory and bulbar dysfunction consistently with natural history of FUS-ALS. In post-mortem analysis, ulefnersen showed good distribution throughout the central nervous system (CNS) even at 2 months after the last treatment. Furthermore, in the same analysis, a reduction in FUS level was observed throughout the CNS (Korobeynikov et al., 2022).

Trial Design & Results

Based on the results from the expanded access program, the FDA allowed the initiation of a multi-centre, three-part study in up to 95 people living with FUS-ALS  (Clinicaltrials.gov ID: NCT04768972).

In the first part of the trial, called FUSION, participants are randomised 2:1 (double blind) to receive ulefnersen or placebo for 60 weeks. This will be followed by an open label extension, where all participants will be treated with ulefnersen for 84 weeks. Participants may continue to receive ulefnersen for up to three years or until ulefnersen becomes commercially available in the participant’s country or until the ulefnersen development program is discontinued.

The study started in 2021 with an estimated primary completion in 2026 and full study completion in 2028. The study has recently completed recruitment. Participants must be at least 10 years old, have signs and symptoms of ALS and a confirmed FUS variant. Ulefnersen will be administered by lumbar intrathecal injection (through spinal tap) every 12 weeks with an additional loading dose at 4 weeks after the first administration.

The primary outcome measure is a change from baseline in functional impairment from day 1 to day 505. Functional impairment will be measured by joint rank analysis of the combined assessment of ALSFRS-R total score, time of rescue (Rescue takes place if there is a deterioration to an ALSFRS-R total score of < 20 points at Study Day 253, or later, that is confirmed after an interval of at least 4 weeks – https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005522-28/NL) or discontinuation from part 1 and entering part 2 due to a deterioration in function, and ventilation assistance-free survival (VAFS). Secondary outcomes include a change in quality of life as assessed by ALSSQOL-R, slow vital capacity, handheld dynamometry, neurofilament light concentration in CSF, and FUS concentration in CSF.

Although the full trial results have not yet been published, a recent report highlighted promising outcomes in at least two of the 12 people treated with ulefnersen. However, aside from these two cases, most participants continued to show functional decline (Shneider et al., 2025).  

Summary

Ulefnersen is an ASO treatment for FUS-ALS. Several people have been treated with ulefnersen under the FDA expanded access program, the phase 1-3 clinical FUSION trial is due to be completed in 2026. The Alliance will continue to update this webpage with new information as it becomes available.

International Alliance of ALS/MND Associations
April 2026


Disclaimer: Consult with a healthcare professional to determine if you could potentially participate in a ulefnersen clinical trial. Always disclose your medical history, including any drugs, natural supplements, or herbal medicines currently being used.

The original language of communication is English and any translation cannot be guaranteed for accuracy of messaging.

Primary Sidebar

Drugs in Development

  • AB Science – Masitinib
  • NurOwn
  • Clene Nanomedicine – CNM-Au8
  • ILB
  • Kadimastem – AstroRx
  • Neuronata-R / Lenzumestrocel
  • NeuroSense – PrimeC
  • NP001
  • Prilenia Therapeutics – Pridopidine
  • SOD1 Therapies & Trials
  • SPG302
  • Regulatory T Cell Enhancing Therapies
  • Ulefnersen

  • Mike Small, UK

    Mike Small, UK

  • Angela Jansen, Germany

    Angela Jansen, Germany

  • Juvenal Bayona Romero, Colombia

    Juvenal Bayona Romero, Colombia

  • John Russo, USA

    John Russo, USA
    final3878

  • Jack Buzby, USA

    Jack Buzby, USA

  • Philip Brindle, England

    Philip Brindle, England

  • Fabio Carvalho, Brazil

    Fabio Carvalho, Brazil

  • Steve Lufkin, USA

    Steve Lufkin, USA
    IMG_3993

  • Gisli Jonasson, Iceland

    Gisli Jonasson, Iceland

  • Wilfried Leusing, Germany

    Wilfried Leusing, Germany

  • Paul Launer, USA

    Paul Launer, USA

  • Steve Gallagher, Canada

    Steve Gallagher, Canada
    Picture1

  • Kirsten Harley, Australia

    Kirsten Harley, Australia

  • Manuel Arn, Switzerland

    Manuel Arn, Switzerland

  • Mauril Belanger, Canada

    Mauril Belanger, Canada

  • Xian-Zhang Niu, China

    Xian-Zhang Niu, China

  • Kris Van Reusel, Belgium

    Kris Van Reusel, Belgium

  • Joanne Pratt, Australia

    Joanne Pratt, Australia

  • Amparo Muriel Engativa, Colombia

    Amparo Muriel Engativa, Colombia

  • Michael Lee, Australia

    Michael Lee, Australia

  • Jon Newsome, USA

    Jon Newsome, USA

  • Lin Yong Yi, Taiwan

    Lin Yong Yi, Taiwan

  • Danny Reviers, Belgium

    Danny Reviers, Belgium
    DannyReviers

  • Olga, Argentina

    Olga, Argentina

  • Lee Millard, England

    Lee Millard, England

  • Alberto Baez Murillo, Colombia

    Alberto Baez Murillo, Colombia

  • Catherine Pearce, Australia

    Catherine Pearce, Australia

  • Bob Spurrier, USA

    Bob Spurrier, USA

  • Federica Mastrosimone, Italy

    Federica Mastrosimone, Italy

  • Andrea Zicchieri, Italy

    Andrea Zicchieri, Italy
    AndreaZicchieri_conSLAncioItaly

  • Semra Gokalp, Turkey

    Semra Gokalp, Turkey

  • Chirag Walia, India

    Chirag Walia, India
    ChiragWalia

  • Brian Lovell, Australia

    Brian Lovell, Australia

  • Robbie Caliste, UK

    Robbie Caliste, UK

  • Michel Perrozzo, France

    Michel Perrozzo, France

  • Bruno Leanza Mantegna, Italy

    Bruno Leanza Mantegna, Italy

  • Irene McCaughey, Australia

    Irene McCaughey, Australia

  • Jo Knowlton, Scotland

    Jo Knowlton, Scotland

  • Peng Yi-Wen, Taiwan

    Peng Yi-Wen, Taiwan

  • Armando González Gómez, Colombia

    Armando González Gómez, Colombia

  • Eddy Lefrancois, Canada

    Eddy Lefrancois, Canada

  • Leon Ryba, Argentina

    Leon Ryba, Argentina

  • Emilienne Verhaegen, Belgium

    Emilienne Verhaegen, Belgium

  • Erwin Coppejans, Belgium

    Erwin Coppejans, Belgium

  • Denis Blais, Canada

    Denis Blais, Canada

  • Steven Gallagher, Canada

    Steven Gallagher, Canada

  • Camilla Heiberg Freiberg, Denmark

    Camilla Heiberg Freiberg, Denmark

  • Lineke Veenstra, Netherlands

    Lineke Veenstra, Netherlands

  • Ismail Gokcek, Turkey

    Ismail Gokcek, Turkey
    ismail_gokcek_alsmnd_tr

  • Greg Heydet, USA

    Greg Heydet, USA

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login